Show simple item record

dc.contributor.authorBrand, DH
dc.contributor.authorBrüningk, SC
dc.contributor.authorWilkins, A
dc.contributor.authorNaismith, O
dc.contributor.authorGao, A
dc.contributor.authorSyndikus, I
dc.contributor.authorDearnaley, DP
dc.contributor.authorHall, E
dc.contributor.authorvan As, N
dc.contributor.authorTree, AC
dc.contributor.authorGulliford, S
dc.coverage.spatialUnited States
dc.date.accessioned2023-10-02T11:34:57Z
dc.date.available2023-10-02T11:34:57Z
dc.date.issued2023-12-01
dc.identifierS0360-3016(23)07628-9
dc.identifier.citationInternational Journal of Radiation: Oncology - Biology - Physics, 2023, pp. S0360-3016(23)07628-9 -
dc.identifier.issn0360-3016
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6003
dc.identifier.eissn1879-355X
dc.identifier.eissn1879-355X
dc.identifier.doi10.1016/j.ijrobp.2023.07.002
dc.description.abstractPURPOSE: Rectal dose delivered during prostate radiation therapy is associated with gastrointestinal toxicity. Treatment plans are commonly optimized using rectal dose-volume constraints, often whole-rectum relative-volumes (%). We investigated whether improved rectal contouring, use of absolute-volumes (cc), or rectal truncation might improve toxicity prediction. METHODS AND MATERIALS: Patients from the CHHiP trial (receiving 74 Gy/37 fractions [Fr] vs 60 Gy/20 Fr vs 57 Gy/19 Fr) were included if radiation therapy plans were available (2350/3216 patients), plus toxicity data for relevant analyses (2170/3216 patients). Whole solid rectum relative-volumes (%) dose-volume-histogram (DVH), as submitted by treating center (original contour), was assumed standard-of-care. Three investigational rectal DVHs were generated: (1) reviewed contour per CHHiP protocol; (2) original contour absolute volumes (cc); and (3) truncated original contour (2 versions; ±0 and ±2 cm from planning target volume [PTV]). Dose levels of interest (V30, 40, 50, 60, 70, 74 Gy) in 74 Gy arm were converted by equivalent-dose-in-2 Gy-Fr (EQD2α/β= 3 Gy) for 60 Gy/57 Gy arms. Bootstrapped logistic models predicting late toxicities (frequency G1+/G2+, bleeding G1+/G2+, proctitis G1+/G2+, sphincter control G1+, stricture/ulcer G1+) were compared by area-undercurve (AUC) between standard of care and the 3 investigational rectal definitions. RESULTS: The alternative dose/volume parameters were compared with the original relative-volume (%) DVH of the whole rectal contour, itself fitted as a weak predictor of toxicity (AUC range, 0.57-0.65 across the 8 toxicity measures). There were no significant differences in toxicity prediction for: (1) original versus reviewed rectal contours (AUCs, 0.57-0.66; P = .21-.98); (2) relative- versus absolute-volumes (AUCs, 0.56-0.63; P = .07-.91); and (3) whole-rectum versus truncation at PTV ± 2 cm (AUCs, 0.57-0.65; P = .05-.99) or PTV ± 0 cm (AUCs, 0.57-0.66; P = .27-.98). CONCLUSIONS: We used whole-rectum relative-volume DVH, submitted by the treating center, as the standard-of-care dosimetric predictor for rectal toxicity. There were no statistically significant differences in prediction performance when using central rectal contour review, with the use of absolute-volume dosimetry, or with rectal truncation relative to PTV. Whole-rectum relative-volumes were not improved upon for toxicity prediction and should remain standard-of-care.
dc.formatPrint-Electronic
dc.format.extentS0360-3016(23)07628-9 -
dc.languageeng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INC
dc.relation.ispartofInternational Journal of Radiation: Oncology - Biology - Physics
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCHHiP Trial Management Group
dc.titleGastrointestinal Toxicity Prediction Not Influenced by Rectal Contour or Dose-Volume Histogram Definition.
dc.typeJournal Article
dcterms.dateAccepted2023-07-03
dc.date.updated2023-10-02T11:34:08Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1016/j.ijrobp.2023.07.002
rioxxterms.licenseref.startdate2023-07-16
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/37433374
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-groupICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-groupICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-groupICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-groupICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-groupICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Stereotactic and Precision Body Radiotherapy
pubs.organisational-groupICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-groupICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-groupICR/Students
pubs.organisational-groupICR/Students/PhD and MPhil
pubs.organisational-groupICR/Students/PhD and MPhil/17/18 Starting Cohort
pubs.organisational-groupICR/ImmNet
pubs.organisational-groupICR/Students/PhD and MPhil/13/14 Starting Cohort
pubs.publication-statusPublished online
icr.researchteamStereotactic Radiother
icr.researchteamTargeted Therapy
icr.researchteamClinic Acad RT Dearnaley
icr.researchteamClin Trials & Stats Unit
dc.contributor.icrauthorBrand, Douglas
dc.contributor.icrauthorCorbett, Anna
dc.contributor.icrauthorGao, Annie
dc.contributor.icrauthorDearnaley, David
dc.contributor.icrauthorHall, Emma
icr.provenanceDeposited by Mr Arek Surman on 2023-10-02. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0360301623076289-main.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/